SCHEMBL25368167

SCHEMBL25368167

CS(=O)(=O)Nc1cccc(NC(=O)c2cc(C(=O)NCCc3cccnc3)cs2)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.50
▸ HDAC2 Q92769 1/20 0.49
▸ HDAC8 Q9BY41 1/20 0.49
▸ HDAC6 Q9UBN7 1/20 0.49
▸ TSHR P16473 1/20 0.46
▸ NAMPT P43490 6/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ ROCK2 O75116 2/20 0.43
▸ DHX9 Q08211 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ROCK1 Q13464 1/20 0.42
▸ PTAFR P25105 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543890 1.00 ALDH1A1 (0.50) ALDH1A1HDAC2HDAC8HDAC6TSHR
SCHEMBL25368472 0.89 LMNA (0.48) ALDH1A1HDAC2HDAC8HDAC6SMN1; SMN2
SCHEMBL30544073 0.82 NAMPT (0.53) NAMPTHTTLMNADHX9L3MBTL1
SCHEMBL25366609 0.82 NAMPT (0.53) NAMPTHTTLMNADHX9L3MBTL1
SCHEMBL25367979 0.80 ALDH1A1 (0.46) ALDH1A1TSHRNAMPTLMNAROCK2
SCHEMBL30543915 0.80 ALDH1A1 (0.46) ALDH1A1TSHRNAMPTLMNAROCK2
SCHEMBL25369891 0.79 DHX9 (0.44) ALDH1A1NAMPTSMN1; SMN2MEN1NPC1
SCHEMBL25368168 0.78 NAMPT (0.51) NAMPTSMN1; SMN2HTTLMNADHX9
SCHEMBL25368280 0.77 DHX9 (0.53) ALDH1A1SMN1; SMN2MEN1RAB9AKMT2A
SCHEMBL30543946 0.77 DHX9 (0.53) ALDH1A1SMN1; SMN2MEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B ALDH1A1 1127/4885HDAC2 2490/4885HDAC8 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback